Skip to main content
Fig. 8 | BMC Immunology

Fig. 8

From: Characteristics of the specific humoral response in patients with advanced solid tumors after active immunotherapy with a VEGF vaccine, at different antigen doses and using two distinct adjuvants

Fig. 8

Changes in platelet VEGF and plasma sVEGFR-2. Platelet VEGF (a) and plasma sVEGFR-2 (b) were expressed in percentages relative to baseline levels (week 0 or pre-vaccination). Discontinued lines represent the cut-off values that indicate: ≥30% increase; ≤-30% decrease; between 30% and -30% stability. (w): is the week when the sample “B” was taken (7–10 days after given re-immunization)

Back to article page

BMC Immunology

ISSN: 1471-2172

Contact us